ClinicalTrials.gg

Program

Bimatoprost Implant System

Also written as “Bimatoprost Implant System (High Dose)” and “Bimatoprost Implant System (Low Dose)”.

Its studies are mostly in Cataract, led by SpyGlass Pharma.

Furthest: phase 3, since Oct 16, 20253 company-led studies, 3 open or runningNext primary completion: Mar 31, 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
SpyGlass Pharma33 open or runningphase 3since Oct 16, 2025Nov 1, 2023Mar 31, 2029phase 3 · NCT07218783

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 1, 2023First study: phase 2 study in CataractFirst studyNCT06120842 · 201 enrolled · United States
  2. Oct 16, 20252 phase 3 studies in CataractNCT07218796, NCT07218783

Ahead

  1. Mar 31, 2029Primary completion: phase 3 study in CataractNCT07218783
  2. May 31, 2029Primary completion: phase 3 study in CataractNCT07218796

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07218796Cataract · United States3RecruitingMay 31, 2029400
NCT07218783Cataract · United States3RecruitingMar 31, 2029400
NCT06120842Cataract · United States2Active, not recruitingJan 31, 2025201

How it is read

Names in the registry

  • “Bimatoprost Implant System”, 2 entries
  • “Bimatoprost Implant System (High Dose)”, 1 entry
  • “Bimatoprost Implant System (Low Dose)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.